Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum

PRESS RELEASE

DUBLIN

,

June 2, 2015

/PRNewswire/ --

Actavis plc

(NYSE: ACT) is proud to participate in today's

White House Forum on Antibiotic Stewardship

, which assembles key Federal and private sector constituencies involved in the development, promotion, and implementation of antibiotic stewardship activities to ensure the responsible use of antibiotics nationwide.

Actavis

is dedicated to helping to bridge the gap between existing treatment options for serious infections caused by difficult-to-treat pathogens and the development of new agents that may help address the urgent threat of antibiotic resistance.

As part of the company's commitment to antibiotic stewardship,

Actavis

recently launched SHARE ID™ (

S

haring

H

ospital data to

A

dvance

R

esearch and

E

nhance patient care in

I

nfectious

D

iseases), a collaborative program to leverage real-world data to accelerate efforts to address antibiotic resistant infections and advance the delivery and effectiveness of care for patients with serious infections due to antibiotic-resistant pathogens. SHARE ID is building a robust and collaborative research platform that will apply state-of-the art analytics to real-world data from participating healthcare institutions. SHARE ID intends to quantify the burden of illness associated with infections due to antibiotic-resistant pathogens, develop decision support tools to assist healthcare decision makers, and conduct comparative effectiveness research to identify optimal treatment strategies. To learn more about the SHARE ID initiative, please visit www.share-ID.com.

"

Actavis

was honored to be asked to participate in the

White House Forum on Antibiotic Stewardship

given our commitment to protecting people from the serious impact of antibiotic resistant infections," said

Gavin R. Corcoran

, MD, Chief Medical Officer at

Actavis

. "As a leading global specialty pharmaceutical company committed to infectious disease treatment innovation, we have a portfolio of therapies that provide some of the newest tools to help to treat a number of the most serious infections, with a focus on enhancing patient care and outcomes for areas of greatest medical need."

The

Actavis

anti-infective portfolio includes three of the six therapies that have been approved by the

U.S. Food and Drug Administration

as part of the

Infectious Disease Society of America's

10x20 initiative — AVYCAZ^™(ceftazidime-avibactam), DALVANCE^® (dalbavancin) and TEFLARO^® (ceftaroline fosamil).

• AVYCAZ is approved for the treatment of adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae andPseudomonas aeruginosa. AVYCAZ received a priority review and fast-track approval based on Phase II data from the company's clinical development program and supporting in vitro data, and as such should be reserved for use in patients who have limited or no alternative treatment options. AVYCAZ is contraindicated in patients with known serious hypersensitivity to AVYCAZ, avibactam containing products, ceftazidime, or other members of the cephalosporin class. Please see additional important safety information below.
• DALVANCE is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is the first and only IV antibiotic approved for the treatment of ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes, and is the first drug designated as a Qualified Infectious Disease Product (QIDP) to receive FDAapproval, as it is intended to treat serious or life-threatening infections. DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin. Please see additional important safety information below.
• TEFLARO is indicated for the treatment of ABSSSI and community acquired bacterial pneumonia (CABP) caused by designated susceptible Gram-positive and Gram-negative isolates. It is the first and only IV cephalosporin with MRSA activity in ABSSSI and the first antibiotic to be approved by the FDA for ABSSSI with clinical response data at 48-72 hours after treatment. TEFLARO was the first antibiotic to receive approval following the launch of the IDSA 10x20 initiative. Known serious hypersensitivity to TEFLARO or other members of the cephalosporin class. Anaphylaxis and anaphylactoid reactions have been reported with ceftaroline.